OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
2.550
-0.260 (-9.25%)
At close: Jul 14, 2025, 4:00 PM
2.580
+0.030 (1.18%)
After-hours: Jul 14, 2025, 6:41 PM EDT
OKYO Pharma Employees
OKYO Pharma had 3 employees as of March 31, 2024. The number of employees decreased by 5 or -62.50% compared to the previous year.
Employees
3
Change (1Y)
-5
Growth (1Y)
-62.50%
Revenue / Employee
n/a
Profits / Employee
-$3,562,623
Market Cap
95.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OKYO News
- 4 weeks ago - Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - Accesswire
- 2 months ago - OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewsWire
- 2 months ago - OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
- 3 months ago - OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewsWire
- 5 months ago - OKYO Pharma Announces Chairman and CEO Acquire Shares - GlobeNewsWire
- 5 months ago - Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited - Accesswire
- 8 months ago - MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 9 months ago - OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewsWire